| Filed On | Filing |
|---|---|
| 12 Nov 2026 | 8-K: Results of Operations and Financial Condition |
| 12 Nov 2026 |
8-K: Entry into a Material Definitive Agreement
As Representatives of the several Underwriters listed in Schedule 1 hereto |
| 10 Nov 2026 |
8-K: Results of Operations and Financial Condition; Other Events
1 Delivering on the promise of Prime Editing Corporate Presentation November 2026 |
| 06 Aug 2026 |
8-K: Results of Operations and Financial Condition
-- IND and CTA clearances in the United States and New Zealand establish a global Phase 1/2 program for PM577a in Wilson disease; study startup activities underway, with initial clinical data in 2027 -- |
| 08 Jul 2026 |
8-K: Other Events
On July 6, 2026, Prime Medicine, Inc. (the "Company") received a final award (the "Final Award") from the arbitration tribunal (the "Tribunal") in the Company's binding arbitration proceedings with Beam Therapeutics, Inc. ("Beam") regard... |
| 08 Jun 2026 |
8-K: Submission of Matters to a Vote of Security Holders
On June 5, 2026, Prime Medicine, Inc. (the “Company”) held its 2026 annual meeting of stockholders (the “Annual Meeting”) in a virtual meeting format via live webcast. Proxies were solicited pursuant to the Company’s definitive proxy sta... |
| 07 May 2026 |
8-K: Results of Operations and Financial Condition
-- On track to file IND and/or CTA for PM577 in Wilson Disease in H1 2026 and for PM647 in AATD mid-2026; initial clinical data from both programs expected in 2027 -- |
| 16 Apr 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
This Employment Agreement (this “Agreement”) is made between Prime Medicine, Inc., a Delaware corporation (the “Company”), and Svetlana Makhni (the “Executive”) and is effective as of April 16, 2026 (the “Effective Date”). |
| 03 Mar 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
-- On track to file IND and/or CTA for Wilson Disease and AATD programs in 1H 2026 and mid-2026, respectively; initial clinical data for both expected in 2027 -- |
| 12 Jan 2026 |
8-K: Regulation FD Disclosure
1 Delivering on the promise of Prime Editing Corporate Presentation January 2026 |
| 07 Nov 2025 |
8-K: Results of Operations and Financial Condition
-- New preclinical data for PM577 in Wilson’s Disease (WD) to be presented at AASLD; on-track to file IND and/or CTA in H1’26, with initial clinical data expected in 2027 -- |
| 08 Sep 2025 |
8-K: Regulation FD Disclosure
1 Delivering on the promise of Prime Editing September 2025 Corporate Presentation |
| 07 Aug 2025 |
8-K: Results of Operations and Financial Condition
-- Announced positive data from two patients in Phase 1/2 clinical trial in Chronic Granulomatous Disease (CGD), providing clinical proof-of-concept for Prime Editing; plan to have regulatory interactions based on current dataset -- |
| 05 Aug 2025 |
8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders
On August 1, 2025 (the “Repricing Date”), Prime Medicine, Inc. (the “Company”) held a special meeting of stockholders (the “Special Meeting”) in a virtual meeting format via live webcast. As further described in Item 5.07 to this Current... |
| 31 Jul 2025 |
8-K: Entry into a Material Definitive Agreement
Prime Medicine, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters listed in Schedule 1 hereto (the “Underwriters”), for whom you are acting as representatives (the “Representatives”), an... |
| 30 Jul 2025 |
8-K: Results of Operations and Financial Condition; Other Events
1 Delivering on the promise of Prime Editing July 2025 Corporate Presentation |
| 15 Jul 2025 |
8-K: Departure/Election of Directors or Officers; Compensation
On July 14, 2025, Prime Medicine, Inc. (the "Company") announced that Jeremy Duffield, M.D. Ph.D., FRCP will step down from his role as Chief Scientific Officer of the Company, effective as of July 15, 2025 (the “Separation”). |
| 05 Jun 2025 |
8-K: Submission of Matters to a Vote of Security Holders
On June 4, 2025, Prime Medicine, Inc. (the “Company”) held its 2025 annual meeting of stockholders (the “Annual Meeting”) in a virtual meeting format via live webcast. Proxies were solicited pursuant to the Company’s definitive proxy sta... |
| 19 May 2025 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure +1 more
Exhibit 99.3 Delivering on the promise of Prime Editing Corporate Presentation May 2025 1 |
| 08 May 2025 |
8-K: Results of Operations and Financial Condition
-- Initial data from Phase 1/2 trial of PM359 for p47phox CGD expected in 2025 -- |
Loading...